Stock-specific action remained in focus on Dalal Street on October 30, with investors reacting to brokerage recommendation, corporate developments and quarterly earnings. Shares of Sun Pharmaceutical Industries rose 1.5 percent after U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ILUMYA (tildrakizumab-asmn) for the treatment of adults with active psoriatic arthritis (PsA).